Cipher Pharmaceuticals (CPHRF) Stock Price, News & Analysis

Company Overview

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: $9.73 to $9.92
• 50-Day Range: $8.75 to $10.64
• 52-Week Range: $6.02 to $14.60
• Volume: 4,973 shs
• Average Volume: 14,231 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CPHRF Stock Analysis - Frequently Asked Questions

How have CPHRF shares performed this year?

Cipher Pharmaceuticals' stock was trading at $9.9660 at the beginning of the year. Since then, CPHRF shares have decreased by 1.3% and is now trading at $9.84.

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) issued its quarterly earnings data on Thursday, May, 5th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.06. The company earned $9.10 million during the quarter, compared to analyst estimates of $10.87 million.

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPHRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/05/2016
• Today: 7/08/2025
• Next Earnings (Estimated): 8/07/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CPHRF
• Previous Symbol: NASDAQ:CPHR
• CIK: N/A
• Web: www.cipherpharma.com
• Phone: (905) 602-5840
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A